GZMB and mantle cell lymphoma: In MCL, Hagner and colleagues reported that lenalidomide increased NK-cell-mediated cytotoxicity against neoplastic cells in preclinical models through secretion of granzyme B and formation of lytic NK cell immunological synapses.